The purine ATP has a prominent regulatory role in CNS function and pathology due to its actions on glial cells -microglia, astrocytes and oligodendrocytes. ATP serves as an apparently ubiquitous 'gliotransmitter' that is released by astrocytes and other cells to activate purine receptors on neighbouring cells. In pathology, the release of ATP mediates both tissue damage and repair by its direct effects on glial cell integrity and survival. The 
BACKGROUND
The main types of glia in the central nervous system (CNS) are astrocytes, oligodendrocytes and microglia, each of which are specialised to perform specific functions to enable CNS function and are integral to all neuropathologies (1) . Astrocytes are multifunctional cells with essential neuron supporting functions, including homeostasis, metabolic support, neurovascular coupling and forming the neuroprotective scar following injury. Furthermore, astrocytes encompass synapses and play a critical role in neurotransmitter uptake and are implicated in synaptic transmission as part of the tripartite synapse (2) . Oligodendrocytes are responsible for myelination, which is essential for rapid axonal communication and higher cognitive function (3, 4) . Microglia have a macrophage function and provide the innate immunity in the CNS (5) . A universal property of glial cells is their responsiveness to ATP through their expression of multiple purine receptors (6) .
Purinoceptors mediate the characteristic responses of glia to CNS insults -astrocyte reactivity, microglial activation and oligodendrocyte/myelin loss. Hence, glial purinoceptors are potential therapeutic targets in multiple CNS disease states.
GLIAL PURINE RECEPTORS
Purine receptors are broadly divided into adenosine (P1) and ATP (P2) receptors, and there is evidence for expression of both groups in different glial cells (6) . P2 receptors (P2R) are further divided into ionotropic P2XR and G-protein coupled metabotropic P2YR, which can be distinguished by a range of agonists and antagonists (7) . There are seven P2XR subunits (P2X 1-7 ), which assemble as trimers to form homomeric and heteromeric receptors with a diverse range of properties (8) , often referred to as glial 'calcium signalling', which is propagated between cells by astroglial release of ATP to activate receptors on neighbouring cells in a 'spillover' or volume transmission manner (11, 12) . Astroglial ATP release in physiological signalling may be primarily vesicular and through connexin-43 (Cx43) hemichannels, although they can also release ATP through pore-forming P2X 7 R, pannexin-1 hemichannels, and volume-regulated anion channels, but the relative importance of the different mechanisms in physiological and pathological signalling is unclear (13) (14) (15) (16) .
Microglia may also release ATP via Cx43 and vesicles (17, 18) , and during ischemia oligodendrocytes can release ATP through pannexin hemichannels (19 'on' signal and is released by astrocytes and by damaged cells following CNS injury to mediate microglial activation (34, 35). There is a prominent role for P2X 7 R in driving microglial activation and proliferation, and P2X 7 R play a major role in the microglial neuroinflammatory response (31, 36, 37). Reactive astrogliosis and glial scar formation is a more protracted process and involves prominent roles for both P2X 7 and P2Y 1 R subtypes (9).
In addition, ATP stimulates the production of pathological levels of pro-inflammatory cytokines and prostaglandin E 2 (PGE 2 ) by astrocytes, resulting in a double hit and increased neuroinflammation and damage (38) . oligodendrocyte loss in ischemia (19) . Oligodendrocytes are highly susceptible to ischemia/hypoxia and enhanced ATP signaling during oxygen-glucose deprivation (OGD)
activates oligodendroglial P2X 7 R and cytosolic Ca 2+ overload, resulting in cell death (19) .
Similarly, the cytotoxic effects of P2X 7 R in OGD have been demonstrated in microglia (56) . 
PURINOCEPTOR SIGNALLING IN THE AGEING BRAIN
There is a loss of glial function in the ageing brain and glial cells are affected at early stages of neurodegenerative processes in Alzheimer's disease (AD) (69) . P2X 1/5 R-mediated calcium signalling in astrocytes was decreased in ageing (27, 70), and there is evidence in mouse models of AD of enhanced calcium signalling in astrocytes associated with P2Y 1 Rmediated release of ATP from reactive astrocytes (71) . Dysregulation of calcium homeostasis is a central thesis in AD (72) , and increased astroglial calcium signalling is observed in animal models of AD and on exposure of astrocytes to β-amyloid (A) (73) . Aβ increases the amount of ATP released from the astrocytes (74), which would have diverse effects on glial cells in AD. Aged microglia express higher levels of P2Y 12 R and respond to extracellular ATP by becoming less dynamic and ramified, opposite to the response of young microglia (75) . These studies are consistent with evidence of microglial senescence and increased inflammation in the ageing brain (76, 77). In addition, there is up-regulation of P2X₇R and increased levels of IL-6, TNF-α, and IL-1 in ageing microglia (78, 79) . A vicious cycle of increased P2Y 1 R-mediated release of ATP from astrocytes and increased expression of microglial P2X 7 R would enhance production of cytokines in microglia.
SUMMARY AND CONCLUSIONS
Purine receptors are central to glial signalling and mediate bipartite effects in glial physiology and pathology, and a common theme is that P2X 7 R and P2Y 1 R mediate damage and repair, respectively. Astrocytes release ATP to act on microglia and oligodendrocytes to integrate them within a glial network. In pathology, ATP released from astrocytes and damaged cells mediates astrocyte reactivity, microglial activation and oligodendrocyte/myelin loss. Moreover, purinergic signalling is likely to play an important role in glial dysfunction in the ageing brain and AD, with consequent effects on neurodegeneration. Hence glial purine receptors are emerging as drug targets and blockade of P2X 7 R reduces pathology and improves outcome in mouse models of stroke, MS, AD and hyperalgesia (54, (80) (81) (82) . Furthermore, P2X 7 R drive microglial activation and increase production of pro-inflammatory cytokines TNF-α, IL-6, and IL-1, which are key mediators of neurodegeneration and oligodendrocyte/myelin damage. In addition, activated microglia express P2Y 13 R and P2Y 14 R (83-85) and P2Y 6 R specifically promote a phagocytic microglial phenotype, whereas P2Y 12 R are associated with demyelinating lesions. Overall, purinergic receptors are potentially key drug targets for modulating astrocytes and microglia and, either directly or indirectly, providing cytoprotection for oligodendrocytes. However, purinergic signalling has a 'Jekyll and Hyde' nature that is mimicked by glial pathology, 
